Renal dysfunction in the setting of HIV/AIDS

Current HIV/AIDS Reports

Volumn 9, Issue 3, 2012, Pages 187-199

  Miro, Jose M ^a   Cofan, Federico ^a   Trullas, Joan C ^b   Manzardo, Christian ^a   Cervera, Carlos ^a   Tuset, Montserrat ^a   Oppenheimer, Federico ^a   Brunet, Mercedes ^a   Moreno, Asuncion ^a   Campistol, Josep M ^a   Gatell, Jose M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF GIRONA   (Spain)

Author keywords

Acute kidney injury; AIDS; Antiretroviral therapy; Chronic kidney failure; Dialysis; HIV Infection; Immunosuppressive agents; Kidney; Kidney transplantation; Proteinuria; Renal dysfunction

Indexed keywords

ACICLOVIR; ADEFOVIR; AMINOGLYCOSIDE; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; ATAZANAVIR; CIDOFOVIR; CIMETIDINE; COBICISTAT; DIDANOSINE; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; FOSCARNET; INDINAVIR; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PENTAMIDINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIMETHOPRIM; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ALBUMINURIA; AMINOACIDURIA; ARTICLE; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRYSTALLURIA; DEATH; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ELECTROLYTE DISTURBANCE; FOLLOW UP; GENOTYPE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GLUCOSURIA; GRAFT SURVIVAL; HEART FAILURE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOLOGY; HIV ASSOCIATED NEPHROPATHY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERLACTATEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICOSURIA; HYPONATREMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY COLIC; KIDNEY DONOR; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY PAPILLA NECROSIS; KIDNEY TRANSPLANTATION; METABOLIC ACIDOSIS; MICROALBUMINURIA; MIXED INFECTION; MORTALITY; NEPHROLITHIASIS; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PATIENT MONITORING; PHOSPHATE METABOLISM; PREVALENCE; PROTEINURIA; RENAL REPLACEMENT THERAPY; RISK FACTOR; SIDE EFFECT; SURVIVAL; TUBULAR DYSFUNCTION; VIRUS LOAD; VITAMIN D DEFICIENCY; CHRONIC KIDNEY FAILURE; FEMALE; MALE; PATHOPHYSIOLOGY; REVIEW; STATISTICS; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ACUTE KIDNEY INJURY; AIDS-ASSOCIATED NEPHROPATHY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEPATITIS C; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; RENAL DIALYSIS; RISK FACTORS;

EID: 84871701204     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-012-0125-9     Document Type: Article

References (123)

1. Kalayjian RC. Renal issues in HIV infection. Curr HIV/AIDS Rep. 2011;8:164-71.
2. Phair J, Palella F. Renal disease in HIV-infected individuals. Curr Opin HIV AIDS. 2011;6:285-9.
3. Bohmart A, Burns G. Renal disease in an urban HIV population in the era prior and following the introduction of highly active antiretroviral therapy. J Natl Med Assoc. 2011;103:513-7.
4. Mocroft A, Reiss P, Gasiorowski J, EuroSIDA Study Group, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010;55:262-70.
5. Brennan A, Evans D, Maskew M, et al. Relationship between renal dysfunction, nephrotoxicity and death among HIVadults on tenofovir. AIDS. 2011;25:1603-9.
6. Baekken M, Os I, Sandvik L, et al. Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population. Nephrol Dial Transplant. 2008;23:3130-7.
7. Szczech L, Menezes P, Byrd Quinlivan E, et al. Microalbuminuria predicts overt proteinuria among patients with HIV infection. HIV Med. 2010;11:419-26.
8. Szczech L, Grunfeld C, Scherzer R, et al. Microalbuminuria in HIV infection. AIDS. 2007;21:1003-9. (Pubitemid 46684331)
9. Overton E, Nurutdinova D, Freeman J, et al. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med. 2009;10:343-50.
10. Ando M, Yanagisawa N, Ajisawa A, et al. Urinary albumin excretion within the normal range is an independent risk for near-term development of kidney disease in HIV-infected patients. Nephrol Dial Transplant. 2011;26:3923-9.
11. Choi A, Li Y, Parikh C, et al. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int. 2010; 478-85.
12. Lopes JA, Melo MJ, Viegas A, et al. Acute kidney injury in hospitalized HIV-infected patients: a cohort analysis. Nephrol Dial Transplant. 2011;26:3888-94.
13. Flandre P, Pugliese P, Cuzin L, et al. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol. 2011;6:1700-7.
14. Tordato F, Cozzi Lepri A, Cicconi P, ICONA Foundation Study Group, et al. Evaluation of glomerular filtration rate in HIV-1- infected patients before and after combined antiretroviral therapy exposure. HIV Med. 2011;12:4-13.
15. Mocroft A, Kirk O, Reiss P, et al. EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010;24:1667-78. A study from the EuroSIDA Study Group that assesses the prevalence of CKD in European HIV-infected patients and the impact of different antiretroviral drug regimens.
16. Déti E, Thiébaut R, Bonnet F, et al. Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med. 2010;11:308-17.
17. Campbell L, Ibrahim F, FisherM, et al. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10:329-36.
18. Di Biagio A, Rosso R,Vitale F, et al. Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: a European case control study. Clin Nephrol. 2011;75:518-23.
19. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120-6.
20. Rawlings MK, Klein J, Klingler EP, et al. Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population. HIV AIDS (Auckl). 2011;3:1-8.
21. Choi A, Li Y, Deeks S, et al. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010;121:651-8.
22. George E, Lucas G, Nadkarni G, et al. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS. 2010;24:387-94.
23. Trullas JC, Mocroft A, Cofan F, et al. EuroSIDA Investigators. Dialysis and renal transplantation in HIV-infected patients: a European survey. J Acquir Immune Defic Syndr. 2010;55:582- 9. The first study that evaluates the prevalence and characteristics of ESRD patients (including patients on dialysis and renal transplant recipients) from the EuroSIDA Cohort.
24. Rodriguez RA, Mendelson M, O'Hare AM, et al. Determinants of survival among HIV-infected chronic dialysis patients. J Am Soc Nephrol. 2003;14:1307-13. (Pubitemid 36514670)
25. Vigneau C, Guiard-Schmid JB, Tourret J, et al. The clinical characteristics of HIVinfected patients receiving dialysis in France between 1997 and 2002. Kidney Int. 2005;67:1509-14. (Pubitemid 40463128)
26. Tourret J, Tostivint I, Tezenas du Montcel S, et al. Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin J Am Soc Nephrol. 2006;1:1241-7.
27. Trullàs JC, Barril G, Cofan F, The Spanish HIV, Infection in Dialysis Study Group, et al. Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006: GESIDA 48/05 study. AIDS Res Hum Retroviruses. 2008;24:1229-35.
28. Jotwani V, Li Y, Grunfeld C, et al. Risk Factors for ESRD in HIVInfected Individuals: Traditional and HIV-Related Factors. Am J Kidney Dis. 2012;59:628-35.
29. George E, Nadkarni GN, Estrella MM, et al. The impact of hepatitis C coinfection on kidney disease related to human immunodeficiency virus (HIV): a biopsy study.Medicine (Baltimore). 2011;90:289-95.
30. Fine DM, Wasser WG, Estrella MM, et al. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J Am Soc Nephrol. 2012;23:343-50.
31. Ramsuran D, Bhimma R, Ramdial PK, et al. The spectrum of HIVrelated nephropathy in children. Pediatr Nephrol. 2012;27:821-7.
32. Chen P, Chen BK, Mosoian A, et al. Virological synapses allow HIV-1 uptake and gene expression in renal tubular epithelial cells. J Am Soc Nephrol. 2011;22:496-507.
33. Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIVassociated nephropathy. J Am Soc Nephrol. 2011;22:2129-37. Excellent study that evaluates APOL1 genotypes in different populations at risk for developing HIVAN. Genetic testing for APOL1 should ideally be included in the clinical practice for care of HIV-infected patients.
34. Medapalli RK, He JC, Klotman PE. HIV-associated nephropathy: pathogenesis. Curr Opin Nephrol Hypertens. 2011;20:306-11.
35. Papeta N, Sterken R, Kiryluk K, et al. The molecular pathogenesis of HIV-1 associated nephropathy: recent advances. J Mol Med (Berl). 2011;89:429-36.
36. D'Agati VD. Pathophysiology of focal segmental glomerulosclerosis: new developments. Curr Opin Nephrol Hypertens. 2012;21 (3):243-50.
37. Salhan D, Sagar A, Kumar D, et al. HIV-associated nephropathy: role of AT2R. Cell Signal. 2012;24:734-41.
38. Salhan D, Pathak S, Husain M, et al. HIV gene expression deactivates redox-sensitive stress response programinmouse tubular cells both in vitro and in vivo. Am J Physiol Renal Physiol. 2012;302: F129-40.
39. Bigé N, Lanternier F, Viard JP et al. Presentation of HIVassociated nephropathy and outcome in HAART-treated patients. Nephrol Dial Transplant. 2012;27:1114-21. Clinical study that analyzes the outcome of HIV-infected patients with HIVAN. It is important to remark that despite antiretroviral therapy, HIVAN led to ESRD in more than half of the cases. It is crucial to have early recognition of this condition.
40. Atta M. Diagnosis and natural history of HIV-associated nephropathy. Adv Chronic Kidney Dis. 2010;17:52-8.
41. Winston J. HIV and CKD epidemiology. Adv Chronic Kidney Dis. 2010;17:19-25.
42. Izzedine H, Harris M, Perazella M. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5:563-73.
43. Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat. 2011;2011:562790.
44. Rockwood N, Mandalia S, Bower M, et al. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS. 2011;25:1671-3.
45. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of oncedaily darunavir/ritonavir versus lopinavir/ritonavir in treatmentnaïve HIV-1-infected patients at 48 weeks. AIDS. 2008;22:1389-97.
46. Viglietti D, Verine J, De Castro N, et al. Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavirboosted atazanavir. Antivir Ther. 2011;16:119-21.
47. Izzedine H, Valantin M, Daudon, et al. Efavirenz urolithiasis. AIDS. 1992;2007:21.
48. Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med. 2006;52:296-7. (Pubitemid 44862772)
49. Bonnet F, Balestre E, Bernardin E, et al. Risk factors for hyperlactataemia in HIV-infected patients. Aquitaine Cohort, 1999- 2003. Antivir Chem Chemother. 2005;16:63-7.
50. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.
51. Calza L, Trapani F, Tedeschi S, et al. Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients. Scand J Infect Dis. 2011;43:656-60.
52. Hhall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773-80.
53. Dauchy FA, Lawson-Ayayi S, de La Faille R, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int. 2011;80:302-9.
54. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867-75.
55. Vrouenraets SM, Wit FW, Fernandez Garcia E, et al. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV- 1-infected patients. HIV Med. 2011;12:620-31.
56. Haverkort ME, van der Spek BW, Lips P, et al. Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature. Scand J Infect Dis. 2011;43:821-6.
57. Kohler JJ, Hosseini SH. Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment. Methods Mol Biol. 2011;755:267-77.
58. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689-96.
59. Post F, Moyle G, Stellbrink H, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral- naïve, HIV-1-infected adults: 48-week results from the ASSERT Study. J Acquir Immune Defic Syndr. 2010;55:49-57.
60. Rodriguez-Novoa S, Labarga P, D'Avolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS. 2010;24:1064-6.
61. Kiser J, Carten M, Aquilante C, et al. The effect of lopinavir/ ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83:265-72.
62. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48:e108-16.
63. Pushpakom SP, Liptrott NJ, Rodríguez-Nóvoa S, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011;204:145-53.
64. Vescini F, Cozzi-Lepri A, Borderi M, et al. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr. 2011;58:163-72.
65. Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIVinfected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011;52:396-405.
66. Levey A, Stevens L, Schmid C, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604- 12.
67. Ibrahim F, Hamzah L, Jones R, et al; on behalf of the UK CHIC/ CKD study group. Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients. Nephrol Dial Transplant. 2012;27:2291-7.
68. Dabrowska MM, Mikula T, Stanczak W, et al. Comparative analysis of the new chronic kidney disease epidemiology collaboration and the modification of diet in renal disease equations for estimation of glomerular filtration rate in HIV type 1- infected subjects. AIDS Res Hum Retroviruses. 2011;27: 809-13.
69. Weinert LS, Camargo EG, Soares AA, et al. Glomerular filtration rate estimation: performance of serum cystatin C-based prediction equations. Clin Chem Lab Med. 2011;49:1761-71.
70. Overton ET, Patel P, Mondy K, et al. Cystatin C and baseline renal function among HIV-infected Persons in the SUN study. AIDS Res Hum Retroviruses. 2012;28:148-55.
71. Estrella MM, Parekh RS, Astor BC, et al. Chronic kidney disease and estimates of kidney function in HIV infection: a crosssectional study in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2011;57:380-6.
72. Neuhaus J, Jacobs D, Baker J, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788-95.
73. Gagneux-Brunon A, Mariat C, Delanaye P. Cystatin C in HIVinfected patients: promising but not yet ready for prime time. Nephrol Dial Transplant. 2012;27:1305-13
74. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24:1923-8.
75. Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection. AIDS. 2009;23:1297-310.
76. Estrella M, Fine D. Screening for chronic kidney disease in HIVinfected patients. Adv Chronic Kidney Dis. 2010;17:26-35.
77. Wyatt C, Hoover D, Shi Q, et al. Microalbunimuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr. 2010;55:73-7.
78. Sola-Del Valle DA, Mohan S, Cheng JT, et al. Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy. Nephrol Dial Transplant. 2011;26:2387-90.
79. Hall A, Edwards S, Lapsley M, et al. Subclinical tubular injury in HIVinfected individuals on antiretroviral therapy: a crosssectional analysis. Am J Kidney Dis. 2009;54:1034-42.
80. Maggi P, Montinaro V, Bellacosa C, et al. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir. AIDS Patient Care STDS. 2012;26:5-11.
81. Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol. 2002;13:1889-93. (Pubitemid 34700614)
82. Trullàs JC, Cofan F, Barril G, Spanish HIV Infection in Dialysis Study Group, et al. Outcome and prognostic factors in HIV-1- infected patients on dialysis in the cART era: a GESIDA/SEN cohort study. J Acquir Immune Defic Syndr. 2011;57(4):276-83.
83. Sawinski D, Wyatt CM, Casagrande L, et al. Factors associated with failure to list HIV-positive kidney transplant candidates. Am J Transplant. 2009;9:1-5.
84. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl JMed. 2010;363:2004- 201. This is the most important experience with renal transplantation in HIV-infected patients. Patient and graft survival rates were high at 1 and 3 years, with no increases in complications associated with HIV infection. A higher rate of acute rejection was found in comparison with the general transplant population.
85. Martina MN, Cofan F, Suarez A, et al. Kidney transplantation and waiting list for renal transplantation for human immunodeficiency virus patients. Transplant Proc. 2011;43:2179-81.
86. Yoon SC, Hurst FP, Jindal RM, et al. Trends in renal transplantation in patients with human immunodeficiency virus infection: an analysis of the United States renal data system. Transplantation. 2011;91:864-8
87. Trullas JC, Cofan F, Tuset M, et al. Renal transplantation in HIV-infected patients: 2010 update. Kidney Int. 2011;79:825-42
88. Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int. 2005;67:1622-9. (Pubitemid 40463144)
89. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8:355-65.
90. Gruber SA, Doshi MD, Cincotta E, et al. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation. 2008;86:269-74.
91. Trullas JC, Cofan F, Cocchi S, et al. Effect of thymoglobulin induction on HIV-infected renal transplant recipients: differences between HIV-positive and HIV-negative patients. AIDS Res Hum Retroviruses. 2007;23:1161-5. (Pubitemid 350014766)
92. Mazuecos A, Fernandez A, Andres A, et al. HIV infection and renal transplantation. Nephrol Dial Transplant. 2011;26:1401-7.
93. Touzot M, Pillebout E, Matignon M, et al. Renal transplantation in HIV-infected patients: the Paris experience. Am J Transplant. 2010;10:2263-9.
94. Miro JM, Torre-Cisneros J, Moreno A, et al. GESIDA/GESITRA- SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005). Enferm Infecc Microbiol Clin. 2005;23:353-62. (Pubitemid 41020547)
95. Bhagani S, Sweny P, Brook G. Guidelines for kidney transplantation in patients with HIV disease. HIV Med. 2006;7:133-9.
96. Grossi P, Tumietto F, Costigliola P, et al. Liver transplantation in HIV-infected individuals: results of the Italian national program. Transplantation. 2006;82 Suppl 2:446.
97. Gilliam BL, Heredia A, Devico A, et al. Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment. AIDS. 2007;21:2108-10. (Pubitemid 47462163)
98. Bosch RJ, Pollard RB, Landay A, et al. Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328). AIDS Res Ther. 2010;7:30.
99. Moscoso-Solorzano GT, Baltar JM, Seco M, et al. Single dose of rituximab plus plasmapheresis in an HIV patient with acute humoral kidney transplant rejection: a case report. Transplant Proc. 2007;39:3460-2. (Pubitemid 350251517)
100. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients.AmJ Transplant. 2007;7:2816-20. (Pubitemid 350045781)
101. Carter JT,MelcherML, Carlson LL, et al. Thymoglobulin-associated CD4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant. 2006;6:753-60. (Pubitemid 43345013)
102. Muller E, Kahn D, Mendelson M. Renal transplantation between HIV-positive donors and recipients. N Engl J Med. 2010;362: 2336-7.
103. Cofan F, Trullas JC, Cervera C, et al. Are HIV-infected donors suitable for renal transplantation? Transplantation. 2011;91:e22-3.
104. Kalayjian RC, Franceschini N, Gupta SK, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS. 2008;22:481.
105. Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant. 2006;21:2809-13. (Pubitemid 44542235)
106. Novak JE, Szczech LA. Management of HIV-infected patients with ESRD. Adv Chronic Kidney Dis. 2010;17:102-10.
107. Alsauskas ZC, Medapalli RK, Ross MJ. Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients. Expert Opin Pharmacother. 2011;12:691-704.
108. Ratnam KK, Feng X, Chuang PY, et al. Role of the retinoic acid receptor-α in HIV-associated nephropathy. Kidney Int. 2011;79:624-34.
109. Zhong Y, Wu Y, Liu R, et al. Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure. Kidney Int. 2012;81:856-64.
110. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40: 1559-85. (Pubitemid 40720806)
111. Panel de expertos de Gesida y Plan Nacional sobre el Sida. National consensus document by GESIDA/National AIDS Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)]. Enferm Infecc Microbiol Clin 2011; 29:209.e1-103
112. Antiretroviral agents product information. European Medicines Agency (EMEA). EPARs for authorised medicinal products for human use. Available at: http://www.emea.europa.eu/htms/human/ epar/a.htm. Accessed March 2012.
113. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-33.
114. Tebas P, Bellos N, Lucasti C, et al. Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function. J Acquir Immune Defic Syndr. 2008;47:342-5. (Pubitemid 351619421)
115. Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008;22:F1-9.
116. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010;24:223-30.
117. Alstrup K, Kangas I, Laursen AL, et al. Renal transplantation in an HIV-infected patient: pharmacokinetic aspects. Scand J Urol Nephrol. 2011;45:216-9.
118. Moreno A, Barcena R, Quereda C, et al. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation. AIDS. 2008;22:547-8. (Pubitemid 351317304)
119. Back D, Gibbons S. The University of Liverpool HIV drug interactions website. Available at: http://www.hiv-druginteractions.org. Accessed March 2012.
120. Tuset M, Miro JM, Codina C, et al. Antiretroviral agents drug-drug interactions website (Spanish). Available at: http:// www.interaccioneshiv.com/. Accessed March 2012.
121. Hossain MM, Coull JJ, Drusano GL, et al. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res. 2002;55:41-52. (Pubitemid 34655641)
122. Sankatsing SU, Hoggard PG, Huitema AD, et al. Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clin Pharmacokinet. 2004;43:823-32. (Pubitemid 39382222)
123. Lepist EI et al. 51st ICAAC, Sep 17-20, 2011, Chicago, IL. Abstract A1-1724.